A controversial debate over the continued usage of angiotensin II receptor blockers and ACE inhibitors among COVID-19 patients with preexisting hypertension arose after the ACE2 receptor became known as the entry factor for SARS-CoV-2 (64). Here, ACE is linked to COVID-19.